|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ILK |
 Gene summary |
| Basic gene Info. | Gene symbol | ILK |
| Gene name | integrin-linked kinase | |
| Synonyms | HEL-S-28|ILK-1|ILK-2|P59|p59ILK | |
| Cytomap | UCSC genome browser: 11p15.4 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001014794.2, NM_001014795.2,NM_001278441.1,NM_001278442.1,NM_004517.3, | |
| Description | 59 kDa serine/threonine-protein kinaseepididymis secretory protein Li 28integrin-linked kinase-2integrin-linked protein kinase | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 602366 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000166333 | ||
| HPRD : 03842 | ||
| Vega : OTTHUMG00000133407 | ||
| Protein | UniProt: Q13418 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ILK | |
| BioGPS: 3611 | ||
| Pathway | NCI Pathway Interaction Database: ILK | |
| KEGG: ILK | ||
| REACTOME: ILK | ||
| Pathway Commons: ILK | ||
| Context | iHOP: ILK | |
| ligand binding site mutation search in PubMed: ILK | ||
| UCL Cancer Institute: ILK | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006468 | protein phosphorylation | 10871859 | GO:0007229 | integrin-mediated signaling pathway | 9366252 |
| Top |
| Ligand binding site mutations for ILK |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | K341 | F342L | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ILK |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | K341 | F342L | -0.355436 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ILK from PDB |
| Top |
| Differential gene expression and gene-gene network for ILK |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ILK |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0236736 | Cocaine-Related Disorders | 2 | Biomarker |
| umls:C0009376 | Colonic Polyps | 1 | Biomarker |
| umls:C0014544 | Epilepsy | 1 | Therapeutic |
| umls:C0007787 | Ischemic Attack, Transient | 1 | Biomarker |
| umls:C0023893 | Liver Cirrhosis, Experimental | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ILK |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ILK go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ATP | ATP | 3kmw | A | K341 | ATP | ATP | 3rep | A | K341 |
| Top |
| Conservation information for LBS of ILK |
| Multiple alignments for Q13418 in multiple species |
| LBS | AA sequence | # species | Species | D339 | RISMADVKFSF | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | D339 | KLSMADTKFSF | 1 | Caenorhabditis elegans | H270 | PTLITHWMPYG | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | H270 | LVIISQYMPFG | 1 | Caenorhabditis elegans | K220 | NDIVVKVLKVR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | K220 | NDIVARILNVQ | 1 | Caenorhabditis elegans | K220 | NDIVVKMLKVR | 1 | Bos taurus | K341 | SMADVKFSFQC | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | K341 | SMADTKFSFQE | 1 | Caenorhabditis elegans | L207 | NHSGELWKGRW | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | L207 | SHSGELWRGKW | 1 | Caenorhabditis elegans | M272 | LITHWMPYGSL | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | M272 | IISQYMPFGSL | 1 | Caenorhabditis elegans | M326 | NSRSVMIDEDM | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | M326 | SSKHVVVDEEL | 1 | Caenorhabditis elegans | N200 | FLAKLNENHSG | 3 | Mus musculus, Rattus norvegicus, Bos taurus | N200 | FLTKLNENHSG | 1 | Homo sapiens | N200 | LITKIAESHSG | 1 | Caenorhabditis elegans | N202 | AKLNENHSGEL | 3 | Mus musculus, Rattus norvegicus, Bos taurus | N202 | TKLNENHSGEL | 1 | Homo sapiens | N202 | TKIAESHSGEL | 1 | Caenorhabditis elegans | N279 | YGSLYNVLHEG | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | N279 | FGSLYNVLHEQ | 1 | Caenorhabditis elegans | R323 | HALNSRSVMID | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | R323 | FYLSSKHVVVD | 1 | Caenorhabditis elegans | S204 | LNENHSGELWK | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | S204 | IAESHSGELWR | 1 | Caenorhabditis elegans | T269 | HPTLITHWMPY | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | T269 | NLVIISQYMPF | 1 | Caenorhabditis elegans | V218 | QGNDIVVKVLK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V218 | QGNDIVARILN | 1 | Caenorhabditis elegans | V218 | QGNDIVVKMLK | 1 | Bos taurus | W271 | TLITHWMPYGS | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | W271 | VIISQYMPFGS | 1 | Caenorhabditis elegans |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |